The first treatment for MCT8 deficiency just cleared the FDA

In MCT8 deficiency, the brain gets too little thyroid hormone while the bloodstream gets too much. On September 28, 2026, the FDA approved Emcitate, a drug from Egetis Therapeutics, and the agency states that it is the first therapy it has approved to treat the symptoms of this very rare genetic disease.

“Until now,” FDA’s Marina Zemskova said, patients living with the condition “had no FDA-approved treatment option.”

A Broken Transporter and a Hormone Stuck in the Blood

The disease is caused by mutations in a gene, SLC16A2, also called MCT8, which makes a protein that carries the thyroid hormone T3 into nerve cells in the developing brain. MedlinePlus describes what follows: the hormone cannot get in, so excess amounts keep circulating in the blood. The condition, also called Allan-Herndon-Dudley syndrome, follows an X-linked recessive pattern and occurs in males, and it produces moderate to severe intellectual disability and problems with movement, with weak muscle tone, joint contractures and, in many people, reliance on a wheelchair by adulthood.

The FDA’s announcement puts it the same way, noting that the brain receives too little of the hormone while excessive levels build up in the bloodstream. Those high levels are what the new drug targets. Its indication is peripheral thyrotoxicosis in patients with MCT8 deficiency, adults and children, and the agency’s “first” is scoped to treating symptoms of the disease rather than curing the underlying transporter defect.

Tiratricol Slips Past the Missing Transporter

Emcitate is tiratricol, supplied as tablets for oral suspension. Hylton Joffe, a director at the agency quoted in the announcement, said the drug sidesteps the broken transporter problem: it can enter cells on its own, without relying on MCT8, and in doing so lowers the elevated thyroid hormone levels in the blood.

FDA granted the drug orphan drug, rare pediatric disease, fast track and breakthrough therapy designations, and reviewed it on a priority basis. Pharmacy Times gives the dosing: 175 micrograms a day for patients weighing 10 kilograms or less and 350 micrograms for heavier patients, adjusted roughly every two weeks to bring total T3 below the midpoint of the age-specific normal range. Contemporary Pediatrics adds that the drug is contraindicated with other thyroid medications.

The agency says two clinical studies supported effectiveness across ages from infants to adults, one international, multicenter, randomized, placebo-controlled trial and one longer open-label study. The announcement itself gives no patient counts. It reports reductions in excess thyroid hormone and improvements in cardiovascular and metabolic symptoms, including systolic blood pressure and heart rate. It lists diarrhea, vomiting, rash and excessive sweating as the most common side effects, and the drug carries a boxed warning against use for obesity or weight loss.

ReTRIACt and the Open-Label Results

Pharmacy Times supplies the figures. The randomized ReTRIACt study enrolled 20 males aged 5 to 31, and 15 reached stable dosing and were randomized to keep taking tiratricol or switch to placebo for 30 days. On placebo, mean total T3 rose by 64.6 ng/dL, against a change of minus 0.2 with continued treatment, and four of the eight placebo patients met rescue criteria versus one of seven on tiratricol. In the 12-month open-label study of 46 males, ages 10 months to 66.8 years, mean total T3 fell from 323.4 to 118.3 ng/dL, heart rate dropped by a mean 8.9 beats per minute and systolic blood pressure by 4.1 mm Hg.

Contemporary Pediatrics reports the same pattern in different units, a mean T3 decline from 4.97 to 1.82 nmol/L at 12 months. The measured changes are in blood hormone, heart rate and blood pressure. Neither outlet reports a result for the brain-related features of the disease, such as the intellectual disability and movement problems that define it, and the indication is limited to peripheral thyrotoxicosis.

The company says it expects Emcitate to reach U.S. patients within eight to ten weeks of approval through its RareLink support program. Egetis chief executive Nicklas Westerholm called the approval “a turning point” for patients and caregivers, according to the company’s release, which also cites a reported median life expectancy of about 35 years for people with the disease.

The placebo comparison is the part of the record that is easiest to quantify, and it rests on 15 people, eight on placebo and seven on treatment, which is the entire randomized evidence behind the finding that four of eight needed rescue. The 12-month open-label study had no comparison group, so its drop in T3 from 323.4 to 118.3 ng/dL is a before-and-after measurement in 46 people, and that smaller randomized withdrawal, with one of seven needing rescue on treatment, is what separates the drug’s effect from the passage of time.

This article was produced with the assistance of AI and reviewed by Morning Overview editors prior to publication.

More from Morning Overview